New markers for breast carcinoma-associated antigen in comparison with CA 15-3

Anticancer Research

Volumn 16, Issue 4 B, 1996, Pages 2339-2343

  Van Dalen, A ^a  

^a GROENE HART HOSPITAL   (Netherlands)

Author keywords

Breast cancer; CA 15 3; IMMULITE BR MA; Truquant(R) BRt

Indexed keywords

ANTIBODY; CA 15-3 ANTIGEN; MONOCLONAL ANTIBODY; TUMOR MARKER;

ARTICLE; BREAST CARCINOMA; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; IMMUNORADIOMETRIC ASSAY; PATIENT MONITORING; PRIORITY JOURNAL; RADIOIMMUNOASSAY; REGRESSION ANALYSIS;

ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CA-15-3 ANTIGEN; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; RADIOIMMUNOASSAY; TUMOR MARKERS, BIOLOGICAL;

EID: 0029788594     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Gendler SJ, Burchell JM, Duhig T, Lamport D, White R, Parker M, Taylor-Papadimitriou J: Cloning of partial cDNA encoding differentiation and tumor-associated mucin glycoproteins expressed by human mammary epithelium. Proc Natl Acad Sci USA 84: 6060-6064, 1987.
2. Gendler SJ, Taylor-Papadimitriou J, Duhig T, Rothhard J, Burchell J: Highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 263: 12820-12823, 1988.
3. Devine PL, Warren JA, Ward BG, McKenzie IFC, Layton GT: Glycosylation and the exposure of tumor-associated epitopes on mucins. J Tumor Marker Oncol 5: 11-26, 1990.
4. Hilgers J, Mensdorff-Pouilly S von, Verstraeten AA, Kenemans P: Quantification of polymorphic epithelial mucin: A challenge for biochemists and immunologists. Scand J Clin Lab Inv 55 Suppl 121: 81-87, 1995.
5. Tobias R, Rothwell C, Wagner J, Green A, Liu YS: Development and evaluation of a radio-immunoassay for the detection of a monoclonal antibody defined breast tumor associated antigen 115D8/DF3. Clin Chem 31: 986, 1985.
6. Hilkens J, Kroezen V, Bonfrer JM, De JBM, Bruning PF: MAM-6 antigen, a new serum marker for breast cancer monitoring. Cancer Res 46: 2582-2587, 1986.
7. Kufe D, Inghirami G, Abe M, Hayes D, Just-Wheeler H, Schlom J: Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 3: 223-231, 1984.
8. Delarue JC, Mouriesse H, Dubois F, Friedman S, May-Levin F: Markers in breast cancer: does CEA add to the detection by CA 15-3? Breast Cancer Res Treat 11: 273-276, 1988.
9. Safi F, Köhler I, Rottinger E, Berg HG: The value of tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen. Cancer 68: 574-582, 1991.
10. Gion M: Serum markers in breast cancer management. Breast 1: 173-178, 1992.
11. Dalen A van: TPS in breast cancer -A comparative study with carcinoembryonic antigen and CA 15-3. Tumor Biol 13: 10-17, 1992
12. Dalen A van, Heering KJ, Barak V, Peretz T, Cremaschi A, Geroni P, Gion M, Saracchini S, Molina R, Namer M, Sticber P, Sturgeon C, Leonard RCF, Einarsson R: Treatment response in metastatic breast cancer. A multicentre study comparing UICC criteria and tumour marker changes. The Breast 5: 81-87, 1996.
13. Dalen A van: Analytical requirements and standardization of CA 15-3. Scand J Clin Lab Invest 55 Suppl 221: 102-104, 1995.